BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 16741616)

  • 1. Hemodynamic effects of one week of carvedilol administration on cirrhotic rats.
    Lin HC; Huang YT; Wei HC; Yang YY; Lee TY; Wang YW; Hou MC; Lee SD
    J Gastroenterol; 2006 Apr; 41(4):361-8. PubMed ID: 16741616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nebivolol treatment increases splanchnic blood flow and portal pressure in cirrhotic rats via modulation of nitric oxide signalling.
    Reiberger T; Payer BA; Schwabl P; Hayden H; Horvatits T; Jäger B; Hummel T; Mitterhauser M; Trauner M; Fuhrmann V; Angermayr B; Peck-Radosavljevic M;
    Liver Int; 2013 Apr; 33(4):561-8. PubMed ID: 23331709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simvastatin effects on portal-systemic collaterals of portal hypertensive rats.
    Huang HC; Wang SS; Lee JY; Chen YC; Lee FY; Lin HC; Chang CC; Lee SD
    J Gastroenterol Hepatol; 2010 Aug; 25(8):1401-9. PubMed ID: 20659230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute administration of carvedilol is more effective than propranolol plus isosorbide-5-mononitrate in the reduction of portal pressure in patients with viral cirrhosis.
    Lin HC; Yang YY; Hou MC; Huang YT; Lee FY; Lee SD
    Am J Gastroenterol; 2004 Oct; 99(10):1953-8. PubMed ID: 15447755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of 1-week losartan administration on bile duct-ligated cirrhotic rats with portal hypertension.
    Yang YY; Lin HC; Huang YT; Lee TY; Hou MC; Lee FY; Liu RS; Chang FY; Lee SD
    J Hepatol; 2002 May; 36(5):600-6. PubMed ID: 11983442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adaptive vasodilatory response after octreotide treatment.
    Yang YY; Lin HC; Huang YT; Lee TY; Lee WC; Hou MC; Lee FY; Chang FY; Lee SD
    Am J Physiol Gastrointest Liver Physiol; 2001 Jul; 281(1):G117-23. PubMed ID: 11408262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carvedilol, a new nonselective beta-blocker with intrinsic anti- Alpha1-adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis.
    Bañares R; Moitinho E; Piqueras B; Casado M; García-Pagán JC; de Diego A; Bosch J
    Hepatology; 1999 Jul; 30(1):79-83. PubMed ID: 10385642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The renal effects of droxidopa are maintained in propranolol treated cirrhotic rats.
    Rodríguez S; Raurell I; Ezkurdia N; Augustin S; Esteban R; Genescà J; Martell M
    Liver Int; 2015 Feb; 35(2):326-34. PubMed ID: 24517276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Terutroban, a TP-receptor antagonist, reduces portal pressure in cirrhotic rats.
    Rosado E; Rodríguez-Vilarrupla A; Gracia-Sancho J; Tripathi D; García-Calderó H; Bosch J; García-Pagán JC
    Hepatology; 2013 Oct; 58(4):1424-35. PubMed ID: 23703868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mixed endothelin receptor antagonist, SB209670, decreases portal pressure in biliary cirrhotic rats in vivo by reducing portal venous system resistance.
    Kojima H; Yamao J; Tsujimoto T; Uemura M; Takaya A; Fukui H
    J Hepatol; 2000 Jan; 32(1):43-50. PubMed ID: 10673066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pioglitazone decreases portosystemic shunting by modulating inflammation and angiogenesis in cirrhotic and non-cirrhotic portal hypertensive rats.
    Schwabl P; Payer BA; Grahovac J; Klein S; Horvatits T; Mitterhauser M; Stift J; Boucher Y; Trebicka J; Trauner M; Angermayr B; Fuhrmann V; Reiberger T; Peck-Radosavljevic M
    J Hepatol; 2014 Jun; 60(6):1135-42. PubMed ID: 24530596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hemodynamic effects of urotensin II and its specific receptor antagonist palosuran in cirrhotic rats.
    Trebicka J; Leifeld L; Hennenberg M; Biecker E; Eckhardt A; Fischer N; Pröbsting AS; Clemens C; Lammert F; Sauerbruch T; Heller J
    Hepatology; 2008 Apr; 47(4):1264-76. PubMed ID: 18318439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contribution of nitric oxide to the pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated rats.
    Liu H; Ma Z; Lee SS
    Gastroenterology; 2000 May; 118(5):937-44. PubMed ID: 10784593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute and chronic haemodynamic and renal effects of carvedilol in patients with cirrhosis.
    Stanley AJ; Therapondos G; Helmy A; Hayes PC
    J Hepatol; 1999 Mar; 30(3):479-84. PubMed ID: 10190732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro and in vivo vascular responses to the L-type calcium channel activator, Bay K 8644, in rats with cirrhosis.
    Moreau R; Oberti F; Lahaye P; Gadano A; Cailmail S; Sogni P; Cales P; Lebrec D
    J Gastroenterol Hepatol; 1998 Dec; 13(12):1254-8. PubMed ID: 9918435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of nitric oxide synthase and cyclooxygenase blockade on expression of cyclooxygenase and hemodynamics in rats with portal hypertension.
    Cao H; Xu J; Liu H; Meng FB; Qiu JF; Wu ZY
    Hepatobiliary Pancreat Dis Int; 2006 Nov; 5(4):564-9. PubMed ID: 17085343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thalidomide ameliorates portal hypertension via nitric oxide synthase independent reduced systolic blood pressure.
    Theodorakis NG; Wang YN; Korshunov VA; Maluccio MA; Skill NJ
    World J Gastroenterol; 2015 Apr; 21(14):4126-35. PubMed ID: 25892862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ablation of primary afferent neurons by neonatal capsaicin treatment reduces the susceptibility of the portal hypertensive gastric mucosa to ethanol-induced injury in cirrhotic rats.
    Camara PR; Ferraz GJ; Franco-Penteado CF; Sbragia-Neto L; Meirelles LR; Teixeira SA; Muscara MN; Velloso LA; Antunes E; Ferraz JG
    Eur J Pharmacol; 2008 Jul; 589(1-3):245-50. PubMed ID: 18555214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement of portal hypertension and hepatic blood flow in cirrhotic rats by oestrogen.
    Sakamoto M; Ueno T; Nakamura T; Sakata R; Hasimoto O; Torimura T; Sata M
    Eur J Clin Invest; 2005 Mar; 35(3):220-5. PubMed ID: 15733078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enoxaparin reduces hepatic vascular resistance and portal pressure in cirrhotic rats.
    Cerini F; Vilaseca M; Lafoz E; García-Irigoyen O; García-Calderó H; Tripathi DM; Avila M; Reverter JC; Bosch J; Gracia-Sancho J; García-Pagán JC
    J Hepatol; 2016 Apr; 64(4):834-42. PubMed ID: 26686269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.